查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933346

全球百白破（白喉、破傷風和百日咳）疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Diphtheria, Tetanus, and Pertussis (DTP) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 請詢問到貨日

價格

百白破（白喉、破傷風和百日咳）疫苗市場成長因素

由於疫苗可預防細菌性疾病的增加和全球免疫活動的擴大，全球百白破（白喉、破傷風和百日咳）疫苗市場正經歷強勁增長。根據 Fortune Business Insights 的數據顯示，2025 年全球百白破疫苗市值為 116.9 億美元。預計該市場將從 2026 年的 134.4 億美元成長到 2034 年的 464.6 億美元，在預測期內複合年增長率高達 16.77%。 北美將在2025年以40.92%的市佔率引領全球市場，這主要得益於其高疫苗接種率和完善的醫療保健基礎設施。

DTP疫苗是一種聯合疫苗，可預防三種嚴重的細菌感染：白喉、破傷風和百日咳。這些疫苗有多種形式，例如DTaP、Tdap和DT/Td疫苗，廣泛用於嬰幼兒、兒童、青少年、成人和孕婦。與這些疾病相關的嚴重併發症，包括肺炎、抽搐、氣道阻塞和肌肉痙攣，顯著增加了全球疫苗的需求。

市場動態

市場驅動因素

細菌性呼吸道感染的日益增加是推動市場成長的主要因素。百日咳由百日咳桿菌引起，具有高度傳染性，對嬰幼兒構成重大風險。 全球百日咳病例報告數量的增加，促使人們更加關注及時接種疫苗和加強劑。兒童免疫接種計劃的重要性日益凸顯，政府積極參與疫苗接種項目，進一步推動了市場擴張。

市場限制因子

儘管成長動力強勁，但疫苗猶豫和對疫苗接種計劃缺乏了解仍然是挑戰，尤其是在低收入國家和發展中地區。宗教信仰、關於疫苗安全性的錯誤訊息以及醫療基礎設施不足，導致錯失接種機會和疫苗接種不完整，從而限制了市場成長並增加了疾病爆發的風險。

市場機會

政府主導的疫苗接種計劃為市場提供了巨大的成長機會。一些國家正在加強其國家免疫規劃，以提高嬰幼兒、兒童和成人的疫苗接種覆蓋率。國際聯盟和組織也積極推廣加強劑接種計畫和聯合疫苗，以減輕疾病負擔和降低醫療成本。 這些措施預計將推動疫苗接種率，並支持市場成長至 2034 年。

市場挑戰

缺乏冷藏配送基礎設施仍然是一項重大挑戰，尤其是在資源匱乏的地區。百白破疫苗從儲存到運輸都需要嚴格的溫度控制。冷藏設施不足和物流不可靠會導致疫苗浪費、效力降低和營運成本增加，從而抑制市場成長。

百白破疫苗市場趨勢

疫苗研發技術的進步正在塑造百白破疫苗市場的未來。傳統的化學滅活疫苗面臨免疫原性降低和需要多次加強免疫等挑戰。因此，製造商越來越多地轉向重組疫苗技術，該技術具有更高的安全性、更強的免疫反應和更持久的保護作用。預計這些創新將在預測期內顯著影響市場成長。

細分市場分析

依技術劃分，滅活疫苗市場佔主導地位，這得益於已獲批准產品的廣泛應用和全球較高的疫苗接種率。然而，由於研發活動的增加，重組疫苗和其他先進技術預計將呈現顯著成長。

依類型劃分，DTaP疫苗市場佔有率最大，這得益於其在兒童免疫規劃中的廣泛應用。 Tdap疫苗市場佔有率也相當可觀，因為它可作為青少年、成人和孕婦的加強疫苗。

依年齡組別劃分，兒童市場佔主導地位。這主要歸功於早期接種疫苗的強烈建議以及兒童較高的疾病風險。成人市場也貢獻顯著，這得益於常規加強免疫接種和產前免疫規劃。

依分銷管道劃分，政府供應商市佔率最大。這主要得益於國家免疫規劃和疫苗批量採購。 由於就醫便利性提高，醫院和零售藥局預計將保持穩定成長。

區域展望

北美地區預計2025年將引領市場。這得益於較高的疾病認知度、強大的疫苗接種覆蓋率以及主要市場參與者的存在。

亞太地區佔第二大市場佔有率，預計將以最高的複合年增長率增長，這主要得益於疾病流行率的上升、政府主導的疫苗接種運動以及價格合理的疫苗供應。

歐洲憑藉先進的醫療保健體系和系統化的疫苗接種計劃，繼續保持著重要的市場佔有率。

拉丁美洲以及中東和非洲地區預計將保持穩定成長，這主要得益於疫苗接種計劃的擴大以及為消除疫苗可預防疾病而加大的力度。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 各國主要疾病流行情形（2025 年）
  • 主要產業趨勢：新產品發布、併購、業務合作等
  • 主要公司產品線分析
  • 概述：白喉、破傷風和百日咳三重疫苗（DTP）接種率國家/地區

第五章 全球百白破（白喉、破傷風與百日咳）疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依技術分類
    • 滅活​​疫苗
    • 其他
  • 市場分析、洞察與預測：依類型分類
    • DTaP疫苗
    • Tdap疫苗
    • DT/Td疫苗
    • 其他
  • 市場分析、洞察與預測：依年齡組別分類
    • 兒科
    • 成人
  • 市場分析、洞察與預測：依通路分類
    • 醫院與零售通路藥房
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美百白破疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲百白破疫苗市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章 亞太地區百白破疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲百白破疫苗市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東和非洲 DTP（白喉、破傷風和百日咳）疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • GSK plc
    • Sanofi
    • Merck &Co., Inc.
    • Boryung Biopharma Co.
    • Serum Institute of India Pvt. Ltd.
    • Wuhan Institute of Biological Products Co., Ltd.
    • BioNet-Asia.
    • Bio Farma
    • Biological E Limited.
Product Code: FBI113648

Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is witnessing robust growth due to the rising burden of vaccine-preventable bacterial diseases and increasing global immunization initiatives. According to Fortune Business Insights, the global DTP vaccines market was valued at USD 11.69 billion in 2025. The market is projected to grow from USD 13.44 billion in 2026 to USD 46.46 billion by 2034, registering a strong CAGR of 16.77% during the forecast period. In 2025, North America dominated the global market with a share of 40.92%, supported by high vaccination coverage and a strong healthcare infrastructure.

DTP vaccines are combination vaccines that protect against three serious bacterial infections-diphtheria, tetanus, and pertussis. These vaccines are widely administered to infants, children, adolescents, adults, and pregnant women in various forms such as DTaP, Tdap, and DT/Td vaccines. The severe complications associated with these diseases, including pneumonia, seizures, airway obstruction, and muscle spasms, have significantly increased the demand for preventive vaccination globally.

Market Dynamics

Market Drivers

The rising prevalence of bacterial respiratory infections is a major factor driving market growth. Pertussis, caused by Bordetella pertussis, is highly contagious and poses a significant risk to infants and young children. The increasing number of reported pertussis cases globally has shifted focus toward timely vaccination and booster doses. Growing emphasis on pediatric immunization schedules and active government participation in vaccination programs are further supporting market expansion.

Market Restraints

Despite strong growth drivers, the market faces challenges due to vaccine hesitancy and lack of awareness regarding immunization schedules, particularly in low-income and developing regions. Religious beliefs, misinformation regarding vaccine safety, and inadequate healthcare infrastructure contribute to missed doses and incomplete immunization, restricting market growth and increasing the risk of disease outbreaks.

Market Opportunities

Government-led vaccination initiatives present significant growth opportunities for the market. Several countries are strengthening national immunization programs to improve vaccine coverage among infants, children, and adults. Global alliances and organizations are also introducing booster programs and combination vaccines to reduce disease burden and healthcare costs. These initiatives are expected to enhance vaccine adoption and support market growth through 2034.

Market Challenges

Limited cold chain infrastructure remains a major challenge, particularly in resource-limited regions. DTP vaccines require strict temperature control throughout storage and transportation. Inadequate refrigeration facilities and unreliable logistics often lead to vaccine wastage, reduced potency, and increased operational costs, thereby restraining market growth.

DTP Vaccines Market Trends

Technological advancements in vaccine development are shaping the future of the DTP vaccines market. Traditional chemically inactivated vaccines are associated with reduced immunogenicity and the need for multiple booster doses. As a result, manufacturers are increasingly shifting toward recombinant vaccine technologies that offer improved safety, stronger immune responses, and longer-lasting protection. These innovations are expected to significantly influence market growth during the forecast period.

Segmentation Analysis

By technology, the inactivated vaccines segment dominated the market, driven by the wide availability of approved products and high global vaccination coverage. However, recombinant and other advanced technologies are expected to grow at a notable rate due to increasing research and development activities.

By type, the DTaP vaccine segment held the largest market share, supported by its widespread use in pediatric immunization programs. The Tdap segment accounted for a substantial share due to its role as a booster vaccine for adolescents, adults, and pregnant women.

By age group, the pediatric segment dominated the market, owing to strong recommendations for early-life immunization and higher disease risk among children. The adult segment also contributed significantly due to routine booster doses and maternal immunization programs.

By distribution channel, government suppliers accounted for the largest share, driven by national immunization programs and bulk procurement of vaccines. Hospital and retail pharmacies are expected to grow steadily due to improved access and convenience.

Regional Outlook

North America dominated the market in 2025, supported by high disease awareness, strong immunization coverage, and the presence of key market players.

Asia Pacific held the second-largest share and is expected to grow at the highest CAGR due to increasing disease prevalence, government vaccination campaigns, and affordable vaccine availability.

Europe maintained a substantial market share, driven by advanced healthcare systems and structured immunization programs.

Latin America and the Middle East & Africa are expected to grow steadily due to rising vaccination initiatives and increasing efforts to eliminate vaccine-preventable diseases.

Competitive Landscape

The market is consolidated, with major players such as GSK plc, Sanofi, and Merck & Co., Inc. holding a significant share. Other notable players include Serum Institute of India, BioNet-Asia, and Wuhan Institute of Biological Products. These companies are focusing on product innovation, strategic collaborations, and regulatory approvals to strengthen their global presence.

Conclusion

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is set for substantial growth over the forecast period, supported by rising bacterial disease prevalence, expanding immunization programs, and continuous advancements in vaccine technologies. With the market valued at USD 11.69 billion in 2025, projected to reach USD 13.44 billion in 2026 and USD 46.46 billion by 2034, increasing government initiatives, pediatric immunization focus, and recombinant vaccine development are expected to sustain long-term market expansion despite challenges related to vaccine awareness and cold chain limitations.

Segmentation By Technology

  • Inactivated
  • Others

By Type

  • DTaP Vaccine
  • Tdap Vaccine
  • DT/ Td vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries, 2025
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries

5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Inactivated
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. DTaP Vaccine
    • 5.2.2. Tdap Vaccine
    • 5.2.3. DT/ Td vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Inactivated
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. DTaP Vaccine
    • 6.2.2. Tdap Vaccine
    • 6.2.3. DT/ Td vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Inactivated
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. DTaP Vaccine
    • 7.2.2. Tdap Vaccine
    • 7.2.3. DT/ Td vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Inactivated
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. DTaP Vaccine
    • 8.2.2. Tdap Vaccine
    • 8.2.3. DT/ Td vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Inactivated
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. DTaP Vaccine
    • 9.2.2. Tdap Vaccine
    • 9.2.3. DT/ Td vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Inactivated
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. DTaP Vaccine
    • 10.2.2. Tdap Vaccine
    • 10.2.3. DT/ Td vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Boryung Biopharma Co.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Serum Institute of India Pvt. Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BioNet-Asia.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Biological E Limited.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2033
  • Table 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 12: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 13: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 14: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 17: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 19: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 22: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 24: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 27: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 28: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 29: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 3: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group 2025 & 2034
  • Figure 5: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 8: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 9: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 10: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 11: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 12: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 13: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 18: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 19: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 20: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 21: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 22: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 23: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 26: Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 27: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 28: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 29: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 30: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 31: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 33: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 36: Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 37: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 38: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 39: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 40: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 41: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 42: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 43: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 46: Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 47: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 48: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Technology, 2025
  • Figure 49: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 50: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Type, 2025
  • Figure 51: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 53: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 56: Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 57: Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Share (%), By Company, 2025